Founders & Management

ENYO Pharma’s team is world class with a crucial mix of pharma senior leadership and scientific excellence in virology to bring the company forward.

Dr Jacky Vonderscher, PhD, co-founder and Chief Executive Officer

Jacky Vonderscher

  • Founder of Vonderscher&Co GmbH
  • Senior executive with a broad R&D experience in the pharmaceutical industry
  • Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
  • Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
  • Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
  • Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
  • Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
  • Board member of Inatherys and ObsEva and SAB member of Inotrem

Pascale Boissel, HEC, CPA, Chief Financial Officer

Pascale Boissel

  • Responsible for all financial and supporting activities
  • Expert in Finance, Corporate Structuring and Operations with 25 years of experience
  • Formerly Deputy CEO and Head of Finance & Administration at Bioaster, a non-profit Technology Research Institute focused on research in Infectious Disease and Microbiology
  • CFO experience in Biotech start-up development with Ipsogen, a molecular diagnostic company, acquired in 2011 by Qiagen
  • Earlier VP Finance in CAC 40 listed French Groups
  • Price Waterhouse Coopers (PWC) former auditor and transactions’ consultant
  • HEC Paris Business School (MBA) and Certified Public Accountant

Dr Benoît de Chassey, PhD, co-founder and Head of Drug Discovery Platform

Benoît de Chassey

  • Principal Investigator of the project since 2006
  • 17 years experience in high-throughput approaches in drug discovery
  • Former project leader in functional screenings at Aptanomics
  • 22 publications, inventor on 7 patents

Dr Raphaël Darteil, PhD, VP Head of non-clinical Development

Rapahaël Darteil

  • Responsible for non-clinical development
  • More than 20 years of experience in R&D project and portfolio management in the Pharma and Biotech industries
  • Scientific expertise in metabolic diseases (including NAFLD/NASH) and in the Nuclear Receptor field
  • COO and Member of the board at Genfit
  • Various positions in the department of Gene Therapy of Aventis both in France and in the US
  • Co-inventor of the patent protecting the use of Elafibranor (Phase III ongoing) for the treatment of NASH patients
  • He owns a PhD in Molecular and Cellular Biology from the University Claude Bernard Lyon I

Delphine Escoula, General and Administrative Manager

Delphine Escoula

  • Manage administration activities of the company in support of the CEO
  • After a few years teaching French in the UK, she joined the business world in 2001 and developed for 15 years skills in manager assistance, customer support, training, performances monitoring and quality control
  • Collaborated on the go-live and development of the Mylan legal softwares, and handled the administration and the training of the 700 users of the EMEA region (2010-2015)

Dr. Nicolas Guyon-Gellin, MD, ESCP, Vice President Corporate Development & Strategy

Nicolas Guyon-Gellin

  • Responsible for Corporate development and strategy
  • Global expert in financial markets and Healthcare
  • Most recently equity research analyst for Morgan Stanley based in London covering various sized listed companies and involved in various Corporate banking activities
  • Former equity research analyst for Exane BNP and Amundi where he was in charge of global pharmaceuticals investment recommendations
  • Graduated from Paris V University as a General Practitioner with a Master degree from ESCP Europe

Dr Eric Meldrum, PhD, Chief Scientific Officer

Eric Meldrum

  • Responsible for the strategy and operational management of pre-clinical drug discovery and development
  • Specialist in drug development, having worked for major pharmaceutical groups and biotechnology companies
  • Former Chief Scientific Officer at Genkyotex and at 3V Biosciences, where he developed portfolios of NOX-inhibiting molecules and of molecules targeting the replication of respiratory viruses respectively
  • Former Director of the Asthma Disease Biology Department at GSK, where he was accountable for the biology associated with more than a dozen drug research and development programmes through to Phase 2 of clinical trials

Laurène Meyniel-Schicklin, Engineer, co-founder and Head of Bioinformatics

Laurène Meyniel-Schicklin

  • Engineer in Biology and Computer Science (Genopole, Evry)
  • Project leader in bioinformatics since 2007
  • More than 10 years experience in omics data management and analysis for drug discovery
  • 18 publications, inventor on 3 patents

Dr Pietro Scalfaro, MD, MBA, Chief Medical Officer

Pietro Scalfaro

  • In charge of strategy and operational management of early-stage clinical drug development
  • Wide range experience in this role in the healthcare sector, working notably in infectious diseases (HCV, via the development of Alisporivir), septicaemia, oncology, Alzheimer’s disease and cardio-respiratory diseases
  • Set up a Personalised Medicine Business Unit at Debiopharm Group and is involved in Swiss eHealth start-up companies
  • Physician, with a degree from the University of Lausanne, certificates in Paediatrics and Intensive Care, and holds an MBA

Pr Patrice André, MD, PhD, co-founder and Medical Advisor

Patrice André

  • Professor of Virology, Charles Mérieux Lyon Sud Medical School, Lyon 1 University
  • Head of clinical virology department at the Hospices Civils de Lyon
  • Team leader at the International Center for Infectiology Research
  • Post-doctoral fellow at New Mexico University
  • > 200 publications in international peer review and high-impact journals, inventor on 7 patents
  • Former member at several scientific committees (Hospices Civils de Lyon, Inserm)
  • Former expert at AFSSAPS
  • Member of several ANRS commissions

Dr Jean-Jacques Garaud, MD, co-founder

Jean-Jacques Garaud

  • Founder/CEO of ADV Life Science SA
  • CEO of Inotrem SA
  • A senior executive with a broad R&D experience in the pharmaceutical industry
  • Most recently Executive VP Head of Pharma Research and Early Development at Roche (2010 to 2012)
  • Executive VP Head of Development and Chief Medical Officer at Roche (2007 to 2010)
  • Previously held other senior positions with Shering-Plough in the USA (1991 to 2001) and with Novartis in the USA and Switzerland (2001 to 2007)
  • Known for his leading role in the development of Interferon alpha, ribavirin and PEG-interferon in hepatitis C virus in the 90s
  • Board member of Circassia, Polyphor, MedDay and Inatherys

Dr Vincent Lotteau, PhD, co-founder and Scientific Advisor

Vincent Lotteau

  • Inserm Research Director, Immunologist
  • Team leader at the International Center for Infectiology Research
  • Member of the Laboratory of Excellence “Ecofect”
  • Founder of the technology transfer team
  • Former director of Inserm Unit « Fundamental and clinical immunology »
  • Former member of Inserm-Transfert steering committee
  • Participated to several governmental missions
  • Post-doctoral fellow at Harvard University and Scripps Clinic Research Foundation
  • Inventor on 9 patents
  • European expert for systems biology

Inserm Transfert Initiative, co-founder

Inserm Transfert Initiative

  • Created in 2005, Inserm Transfert Initiative is a seed-capital company with € 39.7 M capital, further to its second fund raising in 2012.
  • It focuses on providing seed capital for innovative young companies in the biomedical field. Inserm Transfert Initiative supports biotech entrepreneurs in the early stages of their companies’ development.
  • Its current shareholders are BPI France, Inserm Transfert SA, AbbVie, Boehringer Ingelheim Venture Fund, GlaxoSmithKline, Ipsen, LFB, MSD (Merck & Co), Natixis Venture Selection, Pfizer, Sanofi, SHAM, Shire, Sofinnova Partners.